MCID: HPD002
MIFTS: 25

Hepadnavirus Infection

Categories: Rare diseases

Aliases & Classifications for Hepadnavirus Infection

MalaCards integrated aliases for Hepadnavirus Infection:

Name: Hepadnavirus Infection 54
Hepadnaviridae Infections 74

Classifications:



External Ids:

UMLS 74 C0206746

Summaries for Hepadnavirus Infection

MalaCards based summary : Hepadnavirus Infection, also known as hepadnaviridae infections, is related to hepatitis and hepatocellular carcinoma. An important gene associated with Hepadnavirus Infection is TP53 (Tumor Protein P53). The drugs Benzocaine and Peginterferon alfa-2a have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney.

Related Diseases for Hepadnavirus Infection

Diseases related to Hepadnavirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 hepatitis 10.3
2 hepatocellular carcinoma 10.2
3 hepatitis b 10.1
4 liver disease 10.1
5 viral hepatitis 10.1

Graphical network of the top 20 diseases related to Hepadnavirus Infection:



Diseases related to Hepadnavirus Infection

Symptoms & Phenotypes for Hepadnavirus Infection

Drugs & Therapeutics for Hepadnavirus Infection

Drugs for Hepadnavirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 325)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
2
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
3
tannic acid Approved Phase 4,Phase 2,Phase 3,Not Applicable 1401-55-4
4
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
5
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142340-99-6 60871
6
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
7
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
8
glycyrrhizin Approved, Experimental Phase 4,Phase 3 1405-86-3 3495
9
Alprostadil Approved, Investigational Phase 4,Phase 2 745-65-3 149351 5280723
10
Lenograstim Approved, Investigational Phase 4 135968-09-1
11
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 123774-72-1, 83869-56-1
12
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2 143491-57-0 60877
13
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
14
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
15
Methadone Approved Phase 4 76-99-3 4095
16
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Not Applicable 99210-65-8, 215647-85-1
17
rituximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 174722-31-7 10201696
18
Atorvastatin Approved Phase 4 134523-00-5 60823
19
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
20
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21645-51-2
21
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
22 Ethiodized oil Approved, Investigational Phase 4,Phase 2,Not Applicable 8008-53-5
23
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
24
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 302-25-0
25
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Not Applicable 2921-57-5
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
27
Ribavirin Approved Phase 4,Phase 3,Phase 2,Not Applicable 36791-04-5 37542
28
Simethicone Approved Phase 4,Phase 3 8050-81-5
29
Efavirenz Approved, Investigational Phase 4,Not Applicable 154598-52-4 64139
30
Zidovudine Approved Phase 4,Phase 2 30516-87-1 35370
31
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
32
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 62-33-9, 60-00-4 6049
33
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
34
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6, 15438-31-0 23925 27284
35
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
36
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492 6473866
37
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
38
Etravirine Approved Phase 4 269055-15-4 193962
39
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
40
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
41
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-70-2 271
42
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
43
Ergocalciferol Approved, Nutraceutical Phase 4,Not Applicable 50-14-6 5280793
44
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
45
Adefovir Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106941-25-7
46
Tenofovir Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147127-20-6 464205
47
Thymalfasin Investigational Phase 4,Phase 3,Phase 1,Phase 2 62304-98-7
48
Clevudine Investigational Phase 4,Phase 3,Phase 2 163252-36-6
49 Tocotrienol Investigational Phase 4 6829-55-6
50
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Not Applicable 2920-86-7

Interventional clinical trials:

(show top 50) (show all 1158)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Unknown status NCT02894918 Phase 4 Peginterferon alfa-2a
2 Efficacies of Entecavir Add on HBeAg Positive Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment Unknown status NCT02368288 Phase 4 entecavir
3 Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01829685 Phase 4 Entecavir, Adefovir
4 Antiviral Efficacy of Switching to ETV Plus TDF Unknown status NCT01597934 Phase 4 Group A (Zeffix, Sebivo, Hepsera);Group B (Baraclude, Viread)
5 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
6 Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides Unknown status NCT02644538 Phase 4 PegIFN alfa-2a
7 RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure Unknown status NCT02331745 Phase 4 Granulocyte colony-stimulating factor;standard treatment
8 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
9 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
10 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
11 A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
12 Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy Unknown status NCT02081469 Phase 4
13 EFFORT Extension Study Unknown status NCT01529255 Phase 4 telbivudine (ROADMAP);Telbivudine (Standard of Care)
14 An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients Unknown status NCT02560649 Phase 4 Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
15 Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy Unknown status NCT02505009 Phase 4 Engerix-B;Tenofovir;Entecavir
16 Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
17 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
18 3E Extension Study Unknown status NCT01834508 Phase 4 oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
19 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
20 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
21 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
22 Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients Unknown status NCT02991599 Phase 4
23 Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
24 Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients Unknown status NCT02963714 Phase 4
25 Immunogenicity of Hepatitis B Vaccination Among Drug Users Unknown status NCT02959775 Phase 4
26 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
27 Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
28 Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy Unknown status NCT02594293 Phase 4 PegIFN alfa-2a
29 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
30 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
31 Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude Unknown status NCT02523547 Phase 4 Cavir;Baraclude
32 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
33 Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation Unknown status NCT02417207 Phase 4 Entecavir combined long-term low-dose HBIG group intramuscular;Entecavir combined HBIG group short-term high-dose intravenous
34 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
35 Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
36 Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
37 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
38 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
39 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
40 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
41 Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection Unknown status NCT02281266 Phase 4 thymalfasin;nucleoside analog (suggest to use entecavir)
42 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
43 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
44 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
45 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
46 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
47 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
48 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
49 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
50 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm

Search NIH Clinical Center for Hepadnavirus Infection

Genetic Tests for Hepadnavirus Infection

Anatomical Context for Hepadnavirus Infection

MalaCards organs/tissues related to Hepadnavirus Infection:

42
Liver, Testes, Kidney, T Cells, B Cells, Bone, Placenta

Publications for Hepadnavirus Infection

Articles related to Hepadnavirus Infection:

(show all 26)
# Title Authors Year
1
Host Biology and Anthropogenic Factors Affect Hepadnavirus Infection in a Neotropical Bat. ( 30564998 )
2018
2
Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. ( 25772035 )
2015
3
Animal Models and the Molecular Biology of Hepadnavirus Infection. ( 25833941 )
2015
4
Serological and molecular evidence ofA hepadnavirus infection in swine. ( 25780820 )
2015
5
Primary occult hepadnavirus infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the Woodchuck model of hepatitis B virus infection. ( 19193791 )
2009
6
Immune selection during chronic hepadnavirus infection. ( 19669275 )
2008
7
Rapid production of neutralizing antibody leads to transient hepadnavirus infection. ( 14722274 )
2004
8
Woodchuck hepatocytes remain permissive for hepadnavirus infection and mouse liver repopulation after cryopreservation. ( 11584382 )
2001
9
Frequency of spontaneous mutations in an avian hepadnavirus infection. ( 11559794 )
2001
10
Antisense oligonucleotide therapy of hepadnavirus infection. ( 10565037 )
2000
11
Hepadnavirus infection in captive gibbons. ( 10684318 )
2000
12
Low dynamic state of viral competition in a chronic avian hepadnavirus infection. ( 10799602 )
2000
13
Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection. ( 10775634 )
2000
14
Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. ( 9585237 )
1998
15
Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. ( 9419372 )
1998
16
Mouse genetics at work: a new model of chronic hepadnavirus infection. ( 9657123 )
1998
17
Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles. ( 8986943 )
1997
18
Absence of mutations in the p53 tumor suppressor gene in woodchuck hepatocellular carcinomas associated with hepadnavirus infection and intake of aflatoxin B1. ( 9006107 )
1996
19
Therapy of hepadnavirus infection using antisense oligonucleotides. ( 8666519 )
1995
20
Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. ( 8230462 )
1993
21
A preliminary report of a controlled study of thymosin alpha-1 in the woodchuck model of hepadnavirus infection. ( 1514437 )
1992
22
Cellular and molecular mechanisms of hepatocarcinogenesis associated with hepadnavirus infection. ( 1893774 )
1991
23
Alpha-fetoprotein in the woodchuck model of hepadnavirus infection and disease: normal physiological patterns and responses to woodchuck hepatitis virus infection and hepatocellular carcinoma. ( 1701355 )
1990
24
Alpha-fetoprotein in the woodchuck model of hepadnavirus infection and disease: immunochemical analysis of woodchuck alpha-fetoprotein and measurement in serum by quantitative monoclonal radioimmunoassay. ( 1693355 )
1990
25
Liver diseases associated with hepadnavirus infection. A study in duck model. ( 2620307 )
1989
26
Hepadnavirus infection of peripheral blood lymphocytes in vivo: woodchuck and chimpanzee models of viral hepatitis. ( 3485201 )
1986

Variations for Hepadnavirus Infection

Expression for Hepadnavirus Infection

Search GEO for disease gene expression data for Hepadnavirus Infection.

Pathways for Hepadnavirus Infection

GO Terms for Hepadnavirus Infection

Sources for Hepadnavirus Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....